Abstract Number: 0960 • ACR Convergence 2021
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA (STOP-JIA) Study: 24-Month Outcomes
Background/Purpose: The CARRA STOP-JIA study compared the effectiveness of the CARRA Consensus Treatment Plans (CTPs) in achieving clinical inactive disease (CID) in untreated polyarticular JIA…Abstract Number: 1263 • ACR Convergence 2021
Treatment of Pediatric Lupus Is Associated with Significant Re-Organization of B Cell Chromatin
Background/Purpose: Systemic lupus erythematosus (SLE) may be triggered by gene-environment interactions. Data remain scarce on how epigenetic variance contributes to disease risk in pediatric SLE…Abstract Number: 1630 • ACR Convergence 2021
Multisystem Inflammatory Syndrome in Children: Clinical Characteristics and Predictors for Length of Hospitalization
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a recently defined post-infectious phenomena associated with coronavirus disease 2019 (COVID-19). We assessed the demographics, clinical characteristics,…Abstract Number: 0176 • ACR Convergence 2021
Semi-quantitative Chest Computed Tomography (CT) Analysis in Pediatric Rheumatologic (PR) Patients with Diffuse Lung Disease
Background/Purpose: Spiral chest CT (SCT) is commonly used to evaluate subclinical lung disease in pediatric rheumatology. However, there are no validated scoring tools to objectively…Abstract Number: 0766 • ACR Convergence 2021
Baseline Characteristics and Patient Reported Outcomes from a Juvenile Dermatomyositis Registry Inception Cohort
Background/Purpose: Juvenile dermatomyositis (JDM), the most common inflammatory myopathy of children, is rare, with an estimated incidence of 2-4 in 1 million children. Given the…Abstract Number: 0961 • ACR Convergence 2021
Proteomic Profiling of MIS-C Patients Reveals Heterogeneity Relating to Interferon Gamma Dysregulation and Vascular Endothelial Dysfunction
Background/Purpose: Multi-system Inflammatory Syndrome in Children (MIS-C) is a major complication of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in pediatric patients. Children…Abstract Number: 1424 • ACR Convergence 2021
Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study
Background/Purpose: Enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are two conditions that represent pediatric correlates of axial spondyloarthritis (axSpA) and adult psoriatic arthritis (PsA),…Abstract Number: 1631 • ACR Convergence 2021
Predictive Factors for Lack of Response to Treatment in a Long-term Cohort of Patients with Juvenile Idiopathic Arthritis-associated Uveitis
Background/Purpose: Uveitis is the main extraarticular complication of juvenile idiopathic arthritis (JIA) with still a significant impact on JIA morbidity, despite continuous improvement in systemic…Abstract Number: 0244 • ACR Convergence 2021
Development of Candidate Criteria for Axial Disease in Juvenile Spondyloarthritis: An International Collaboration
Background/Purpose: As part of a larger study developing classification criteria for axial disease in children with spondyloarthritis (SpA), the objective of this project phase was…Abstract Number: 0767 • ACR Convergence 2021
Medication Use in Pediatric Lupus in the Childhood Arthritis and Rheumatology Research Alliance Registry
Background/Purpose: Black and Hispanic children with pediatric lupus (pSLE) have higher morbidity and mortality, but the extent to which differences in outcomes may be related…Abstract Number: 0974 • ACR Convergence 2021
Use of Disease-Modifying Anti-Rheumatic Drug Associated with Lower Incidence of Anti-Tumor Necrosis Factor Induced Psoriasis in Children with Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis
Background/Purpose: Tumor necrosis factor inhibiting (TNFi) therapies are associated with new-onset psoriasis in children with inflammatory bowel disease (IBD) and juvenile idiopathic arthritis (JIA). We…Abstract Number: 1614 • ACR Convergence 2021
Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain
Background/Purpose: Chronic musculoskeletal pain (CMP) affects up to 40% of youth and is associated with physical disability and psychological distress. Resilience coaching interventions, such as…Abstract Number: 1633 • ACR Convergence 2021
Epidemiology of Musculoskeletal Manifestations in Paediatric Inflammatory Bowel Disease: A Systematic Review
Background/Purpose: Paediatric inflammatory bowel disease (p-IBD) is a chronic and relapsing gastrointestinal disorder of childhood with associated long-term morbidity. Several extraintestinal manifestations (EIMs) are described,…Abstract Number: 0246 • ACR Convergence 2021
Macrophage Activating Syndrome in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Biological Drugs
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (SJIA) is the most acute and severe form of JIA. Despite the substantial evidence supporting the effectiveness of biologic drugs…Abstract Number: 0769 • ACR Convergence 2021
Renal Outcomes in 1528 Childhood-onset Systemic Lupus Erythematosus Patients: A Brazilian Multicenter Study
Background/Purpose: Lupus nephritis is a frequent manifestation in childhood-onset systemic lupus erythematosus (cSLE) and has a great potential for chronic kidney disease (CKD), requiring dialysis…
- « Previous Page
- 1
- …
- 32
- 33
- 34
- 35
- 36
- …
- 52
- Next Page »